Clinical trial NCT04730843: A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors
Official title: An Open-label, Multicenter, Dose-escalation and Cohort Expansion Phase 1 Clinical Study of ES102 Administered as a Single Agent in Patients With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Solid Tumors
Neoplasms
Malignant Tumor
Keywords: ES102
solid tumor
phase 1
OX40
INBRX-106
Lead sponsor: Elpiscience Biopharma, Ltd.
Sponsor class: INDUSTRY
First posted: 2021-01-29
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety, tolerance, Dose-Limiting Toxicity (DLT), Maximum tolerated dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of ES102 (OX40 Agonist) administered as a single agent in patients with advanced solid tumors.


Eligibility criteria: Inclusion Criteria:

1. Ability to understand and the willingness to sign a written informed consent form.
2. Males or females aged ≥18 years.
3. Part A: Subjects with pathological or cytological diagnosed advanced solid tumor, whose disease has progressed despite standard therapies, or for whom no further standard therapy exists, or who is unsuitable for available standard therapies.

   Part B: Subjects with NSCLC, ESCC, NPC, GI or Cervical cancers, with advanced disease, which has progressed despite all standard therapies or for whom no standard therapy exists, or who is unsuitable for available standard therapies.

   All subjects with NSCLC have documentation of absence of tumor activating EGFR mutation and absence of ALK and ROS1 gene rearrangements.
4. PD-L1 by IHC result mandatory but any score allowed .
5. At least one measurable lesion is required (RECIST v1.1)
6. Adequate hematologic, coagulation, hepatic and renal function as defined per protocol.
7. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.
8. Estimated life expectancy, in the judgment of the investigator, of at least 12 weeks.
9. Male and female subjects of childbearing potential and their spouses must be willing to use feasible contraceptive methods considered effective by the investigator, from the time of signing informed consent and for the duration of study participation through 3 months, following the last dose of study drug. Postmenopausal women are considered to have no fertility potential only if menostasis lasts for at least 12 months.

Exclusion Criteria:

1. Prior exposure to OX40 agonists.
2. Known allergies to CHO-produced antibodies, which in the opinion of the Investigator suggests an increased potential for an adverse hypersensitivity to ES102.
3. Receipt of any anticancer investigational product or any approved anticancer drug(s) or biological product(s) within 4 weeks prior to the first dose of study drug with certain exceptions.
4. Patients with other malignancies within 2 years before screening shall be excluded in Part B. Some exceptions as defined per protocol apply.
5. Hematologic malignancies (e.g., ALL, AML, MDS, CLL, CML, NHL, Hodgkin's lymphoma and multiple myeloma)
6. Known or active primary central nervous system (CNS) tumors, leptomeningeal disease and CNS metastases. Exception: subjects with previously treated, asymptomatic, and clinically stable CNS metastases may be allowed study entry if certain criteria apply in Part B.
7. Grade ≥ 3 immune-related adverse events (irAEs) or irAE that lead to discontinuation of prior immunotherapy. Some exceptions as defined per protocol apply.
8. Active autoimmune disease or documented history of autoimmune disease that required systemic steroids or other immunosuppressive medications. Certain exceptions as defined in protocol apply.
9. Treatment with systemic immunosuppressive medications within 4 weeks prior to the first dose of study drug. Certain exceptions as defined in protocol apply.
10. History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection for Part A. Exceptions as defined in protocol for Part B will apply.
11. Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or pneumonitis requiring treatment with steroids or other immunosuppressive medications.
12. Clinically significant cardiac condition, including myocardial infarction, uncontrolled angina, cerebrovascular accident, or other acute uncontrolled heart disease \< 6 months; left ventricular ejection fraction (LVEF) \< 50%; New York Heart Association (NYHA) Class III or IV congestive heart failure; or uncontrolled hypertension.
13. Active, hemodynamically significant pulmonary embolism within 3 months prior to the first dose of study drug.
14. Major surgery within 4 weeks prior to enrollment on this trial.
15. Systemic anti-infectious drug treatments within 4 weeks prior to the first dose of study drug.
16. Prior organ allograft transplantations or allogeneic peripheral blood stem cell (PBSC) or bone marrow (BM) transplantation.
17. Pregnant or nursing females.
18. Any known, documented, or suspected history of substance abuse that would preclude subject from participation, unless clinically justified (i.e., will not interfere with study participation and/or will not compromise trial objectives) per judgment of the Investigator and with approval of the Medical Monitor or Study Director.
19. The subject is inappropriate to participate in this study for other reasons in the judgment of the Investigator.

Primary outcomes:
measure: Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of of ES102
timeFrame: 2-3 years
measure: Number of participants with adverse events and serious adverse events of ES102
timeFrame: 2-3 years
Secondary outcomes:
measure: Area under the serum concentration time curve (AUC) of ES102
timeFrame: 2-3 years
measure: Maximum observed serum concentration (Cmax) of ES102
timeFrame: 2-3 years
measure: Trough observed serum concentration (Ctrough) of ES102
timeFrame: 2-3years
measure: Time to Cmax (Tmax) of ES102
timeFrame: 2-3years
measure: Immunogenicity of ES102
timeFrame: 2-3years
measure: Anti-tumor activity of ES102
timeFrame: 2-3years
Other outcomes:
Locations:
city: Changchun
country: China
facility: Jilin Cancer Hospital
state: Jilin
Study officials:
References: